Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) EBIT (2016 - 2025)

Historic EBIT for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to $163.1 million.

  • BeOne Medicines' EBIT rose 23562.88% to $163.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.7 million, marking a year-over-year increase of 12093.54%. This contributed to the annual value of -$568.2 million for FY2024, which is 5295.34% up from last year.
  • BeOne Medicines' EBIT amounted to $163.1 million in Q3 2025, which was up 23562.88% from $87.9 million recorded in Q2 2025.
  • BeOne Medicines' 5-year EBIT high stood at $190.6 million for Q4 2021, and its period low was -$474.8 million during Q2 2021.
  • Over the past 5 years, BeOne Medicines' median EBIT value was -$261.3 million (recorded in 2024), while the average stood at -$209.5 million.
  • Per our database at Business Quant, BeOne Medicines' EBIT crashed by 73175.99% in 2022 and then soared by 23562.88% in 2025.
  • BeOne Medicines' EBIT (Quarter) stood at $190.6 million in 2021, then plummeted by 345.92% to -$468.6 million in 2022, then grew by 18.1% to -$383.8 million in 2023, then soared by 79.31% to -$79.4 million in 2024, then skyrocketed by 305.37% to $163.1 million in 2025.
  • Its EBIT was $163.1 million in Q3 2025, compared to $87.9 million in Q2 2025 and $11.1 million in Q1 2025.